Dr. Ian Krop, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana Farber Cancer Institute

  Fellowship Hospital

• Johns Hopkins Hospital

  Residency Hospital

• Johns Hopkins Hospital

  Internship Hospital

• Johns Hopkins School Of Medicine

  Medical School, 1996

• Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study, 2018-10-26

• Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer, 2015-07-01

• Chemotherapy-Related Amenorrhea after Adjuvant Paclitaxel-Trastuzumab (APT Trial), 2015-05-16

• PIK3CAH1047Rand Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling, 2015-12-07

• Massively-parallel enrichment of minor alleles for mutational testing via low-depth duplex sequencing, 2022-03-17

• A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer, 2014-01-27

• Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists, 2020-05-14

• HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer, 2016-06-03

• PI3K-p110a mediates resistance to HER2-targeted therapy in HER2+,PTEN-deficient breast cancers, 2015-10-26

• Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab, 2021-05-03

• The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy, 2019-05-06

• Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry, 2013-06-18

• CDK4/6 inhibition triggers anti-tumor immunity, 2017-08-16

• Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer, 2011-03-17

• Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients, 2021-06-11

• Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer, 2018-07-23

• Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer, 2018-05-23

• Tumor mutational burden andPTENalterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer, 2020-02-04

• Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial, 2016-05-04

• Unraveling the clinicopathological features driving the emergence ofESR1mutations in metastatic breast cancer, 2018-08-02

• Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study, 2014-05-24

• PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity, 2016-02-09

• Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases, 2020-11-30

• Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer, 2018-06-07

• The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+breast cancer, 2021-06-08

• Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer, 2020-03-13

• Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer, 2022-12-01

• Prevalence of germlineTP53mutations in HER2-positive Breast Cancer Patients, 2013-04-12

• A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer, 2022-05-10

• Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases, 2019-08-22

• Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer, 2016-03-15

• Response and resistance to BET bromodomain inhibitors in triple negative breast cancer, 2016-01-06

• Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer, 2020-08-21

• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors, 2016-03-14

• Disruption Of Laminin-Integrin-CD151-FAK Axis Sensitizes Breast Cancer Cells To ErbB2 Antagonists, 2010-03-02

• The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer, 2021-02-16

• TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases, 2019-03-12

• Genomic characterization ofde novometastatic breast cancer, 2020-12-08